Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
123,5 USD | -2,89% | -6,03% | +28,03% |
17/05 | SAREPTA THERAPEUTICS, INC. : prospettiva positiva di Mizuho Securities | ZM |
14/05 | SAREPTA THERAPEUTICS, INC. : Oppenheimer da Neutral a Buy | ZM |
Attività
Numero di dipendenti: 1 314
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100,0
%
| 933 | 100,0 % | 1 243 | 100,0 % | +33,26% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 933 | 100,0 % | 1 243 | 100,0 % | +33,26% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 26/06/17 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 01/01/15 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 48 | 01/06/18 | |
Will Tilton
HRO | Human Resources Officer | - | - |
Alison Nasisi
HRO | Human Resources Officer | - | - |
Dallan Murray
PRN | Corporate Officer/Principal | - | 01/01/13 |
Diane Berry
PRN | Corporate Officer/Principal | - | 01/12/11 |
Ryan Brown
LAW | General Counsel | 46 | 01/01/18 |
Joseph Bratica
AUD | Comptroller/Controller/Auditor | 60 | 01/03/17 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 26/06/17 |
M. Wilsey
CHM | Chairman | 71 | 31/03/09 |
Richard Barry
BRD | Director/Board Member | 65 | 02/06/15 |
Director/Board Member | 86 | 01/06/10 | |
Stephen Mayo
BRD | Director/Board Member | 62 | 16/11/21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 02/06/15 |
Michael Chambers
BRD | Director/Board Member | - | 02/06/22 |
Kathryn Boor
BRD | Director/Board Member | 65 | 02/06/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 94 523 766 | 89 825 408 ( 95,03 %) | 0 | 95,03 % |
Coordinate società
Sarepta Therapeutics, Inc.
215 First Street Suite 415
02142, Cambridge
+617 274 4000
http://www.sareptatherapeutics.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+28,03% | 12,02 Mrd | |
+12,30% | 116 Mrd | |
+12,15% | 106 Mrd | |
-8,14% | 23,89 Mrd | |
-1,69% | 21,58 Mrd | |
-10,60% | 18,96 Mrd | |
-41,25% | 16,96 Mrd | |
-15,33% | 16,33 Mrd | |
+5,80% | 14,14 Mrd | |
-2,52% | 7,58 Mrd |
- Borsa valori
- Azioni
- Azione SRPT
- Società Sarepta Therapeutics, Inc.